Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$21.9M-62.6%-$13.47M+5.2%-$14.21M+15.8%-$16.87M+41.1%-$28.66M-58.3%
$585K+8.7%$538K+39.7%$385K+11.0%$347K+14.5%$303K+30.6%
$5.41M+25.6%$4.3M-3.9%$4.48M-6.7%$4.8M+71.1%$2.8M+80.7%
-$23.83M-176%-$8.63M+1.2%-$8.73M+35.8%-$13.59M+31.9%-$19.98M-39.9%
$1.38M-27.6%$1.9M+48.4%$1.28M-27.9%$1.78M+434%$333K-40.6%
$21.84M-$179.12M-504%
$623K-41.2%$1.06M-60.0%$2.65M+6,217%$42K-100.0%$211.12M+271%
-$1.37M$3.41M$12.02M-7.2%
-$25.21M-139%-$10.53M-5.2%-$10.01M+34.9%-$15.37M+24.3%-$20.31M-36.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Beta Bionics, Inc. Common Stock generate?
Beta Bionics, Inc. Common Stock (BBNX) generated -$54.8M in operating cash flow over the trailing twelve months.
What is Beta Bionics, Inc. Common Stock's free cash flow?
After $6.3M of capital expenditures, Beta Bionics, Inc. Common Stock's free cash flow was -$61.1M over the trailing twelve months, down 2.9% year over year.
Where does Beta Bionics, Inc. Common Stock's cash flow data come from?
Every line is extracted from Beta Bionics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.